Omeros (OMER) Projected to Post Earnings on Thursday

Omeros (NASDAQ:OMER - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect Omeros to post earnings of ($0.60) per share and revenue of $0.40 million for the quarter.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Monday, March 31st. The biopharmaceutical company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter last year, the company earned ($0.15) earnings per share. On average, analysts expect Omeros to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Omeros Price Performance

NASDAQ:OMER opened at $4.43 on Wednesday. The company has a market cap of $258.30 million, a P/E ratio of -1.92 and a beta of 2.42. Omeros has a one year low of $3.00 and a one year high of $13.60. The firm's fifty day moving average price is $7.28 and its two-hundred day moving average price is $8.15.

Wall Street Analysts Forecast Growth

OMER has been the topic of several research analyst reports. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Tuesday, April 1st. StockNews.com cut Omeros from a "hold" rating to a "sell" rating in a report on Wednesday, April 9th. Finally, D. Boral Capital reissued a "buy" rating and set a $36.00 price target on shares of Omeros in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Omeros presently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.